Nanoscope Therapeutics to Present at 2026 American Society of Retina Specialists Annual Scientific Meeting
Jordi Monés, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular Degeneration Benjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b/3 Trial of MCO-010 in Retinitis Pigmentosa MONTREAL,...
Jordi Monés, MD, PhD, to Introduce First Direct-to-Phase 2 Randomized, Controlled Trial of Optogenetic Therapy in Macular Degeneration Benjamin Bakall, MD, PhD, to Present Durable 3-Year REMAIN Follow-Up Data from the RESTORE Phase 2b/3 Trial of MCO-010 in Retinitis Pigmentosa MONTREAL,...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.